Potential of hexapeptide succinate in the pharmacotherapy of respiratory diseases: resolution of the Board of Experts

Abstract

The expansion of available treatment methods for community-acquired pneumonia (CAP) is more relevant than ever. Drugs with pronounced anti-in-flammatory, antioxidant, and regenerating properties are needed to help prevent lung damage and minimize potential complications as part of complex therapy. The purpose of the publication of the resolution of the Board of Experts was to discuss the efficacy and safety of hexapeptide succinate (Amberwin® Pulmo) in the treatment of respiratory diseases, primarily CAP. The Board of Experts met on February 26, 2026 in Moscow under the chairmanship of the Doctor of Medicine, Professor, Academician of Russian Academy of Sciences S.N.Avdeev. Results. Phase III clinical trials demonstrated the following advantages of hexapeptide succinate: anti-inflammatory, immunoregulatory, antioxidant, reparative and organoprotective effects; rapid reduction in the level of pro-inflammatory cytokines, acceleration of clinical effect, reduction of hospitalization time, and cost-effective-ness. Conclusion. The data presented justify the inclusion of hexapeptide succinate in clinical guidelines for the treatment of CAP in adults.